Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Motzer Helps Set the Pace of Discovery in Kidney Cancer Research

May 17th 2018

Robert J. Motzer, MD, has been at the forefront of research into renal cell carcinoma for nearly 30 years, with his work contributing to the approval of at least 8 new drugs.

Biomarker Dilemma Persists With Immunotherapy in Bladder Cancer

May 15th 2018

The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.

Harshman Addresses Potentially Practice-Changing Adjuvant Therapy Trials in RCC

May 14th 2018

Lauren C. Harshman, MD, discusses ongoing clinical trials examining the incorporation of immune therapies into practice.

Focusing on Risk Stratification in Prostate Cancer

May 14th 2018

The National Comprehensive Cancer Network has overhauled its guidelines for managing prostate cancer with a greater emphasis on risk stratification for molecular testing and therapy choices.

Standard of Care Continues to Shift in RCC

May 11th 2018

Toni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.

Dr. Balar on Impact of Durvalumab Plus Tremelimumab in Bladder Cancer

May 10th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the impact of the combination of durvalumab (Imfinzi) plus tremelimumab in metastatic bladder cancer.

Dr. Harshman Discusses the Potential for New RCC Treatments

May 10th 2018

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses the potential for new treatment options in renal cell carcinoma.

Expert Underscores Importance of AE Management in GU Cancers

May 10th 2018

Xiao X. Wei, MD, MAS, discusses managing possible adverse events of different systemic therapies in kidney and bladder cancer.

Sonpavde Navigates the Evolving Bladder Cancer Landscape

May 9th 2018

Guru P. Sonpavde, MD, navigates through the treatment landscape of urothelial carcinoma.

Combinations Take Hold in Kidney Cancer

May 7th 2018

Bradley A. McGregor, MD, discusses the growth of combination therapy in the treatment of patients with kidney cancer.

Where Are the Physicians?

May 6th 2018

Raoul S. Concepcion, MD, FACS, discusses the current state of physicians the urology practice.

Urology Practice Uses Robotic Surgery to Improve Outcomes

May 5th 2018

Since 2005, physician partners at Comprehensive Urologic Care have been using a form of clampless surgery, which they developed at their practice, for partial nephrectomies.

New Nivolumab Dosing Schedules Approved in Europe

April 26th 2018

The European Commission has approved 2 new dosing schedules for nivolumab across several tumor types.

Dr. Wei on Immune-Related Adverse Events in GU Cancers

April 24th 2018

Xiao X. Wei, MD, MAS, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immune-related adverse events (irAE) in genitourinary (GU) cancers.

Ramucirumab Misses OS Endpoint in Phase III Urothelial Carcinoma Trial

April 23rd 2018

Combining ramucirumab with docetaxel in patients with locally advanced or unresectable metastatic urothelial carcinoma who progressed on platinum-based chemotherapy led to a positive trend, but not a statistically significant improvement, in overall survival.

Rocapuldencel-T Falls Short in mRCC

April 19th 2018

An interim analysis revealed that the immunotherapy rocapuldencel-T is unlikely to meet any of the primary endpoints of the phase III ADAPT trial in patients with metastatic renal cell carcinoma.

Anti-PD-1 Biomarker Analysis Shows Promise for MDSCs, IFN-Gamma

April 18th 2018

A search for molecular guidance in the use of anti-PD-1 therapy in urothelial cancer pointed toward myeloid-derived suppressor cells as a potentially useful biomarker.

Dr. Sharma Discusses Updates from CheckMate-275 in Bladder Cancer

April 17th 2018

Padmanee Sharma, MD, PhD, scientific director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, discusses updated findings from the CheckMate-275 trial in bladder cancer during an interview at the 2018 AACR Annual Meeting.

Dr. Balar on Results of Durvalumab Plus Tremelimumab in Bladder Cancer

April 17th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the results of a study investigating durvalumab (Imfinzi) plus tremelimumab in patients with metastatic urothelial cancer.

Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC

April 16th 2018

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).